Analysts Set Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Price Target at $3.23

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has earned an average rating of “Hold” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $3.2250.

Several research analysts have commented on LXRX shares. Wall Street Zen downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd.

Insider Activity

In other news, Director Invus Global Management, Llc acquired 1,538,462 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were acquired at an average cost of $1.30 per share, with a total value of $2,000,000.60. Following the acquisition, the director directly owned 1,538,462 shares of the company’s stock, valued at approximately $2,000,000.60. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 13.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Large investors have recently bought and sold shares of the business. Hudson Bay Capital Management LP purchased a new stake in Lexicon Pharmaceuticals during the second quarter valued at $26,000. R Squared Ltd bought a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter worth about $28,000. Security National Bank of Sioux City Iowa IA purchased a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter valued at about $31,000. Leonteq Securities AG bought a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $34,000. Finally, EntryPoint Capital LLC bought a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $39,000. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Trading Down 3.3%

Lexicon Pharmaceuticals stock opened at $1.47 on Friday. Lexicon Pharmaceuticals has a 1 year low of $0.28 and a 1 year high of $1.83. The firm’s 50 day moving average price is $1.29 and its 200-day moving average price is $1.30. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.64 and a quick ratio of 5.63. The stock has a market cap of $534.30 million, a P/E ratio of -7.74 and a beta of 0.98.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.